| BetaShares Australian Bank Senior Floating Rate Bond ETF (QPON) |
Financials |
$1,612 |
Final Distribution Announcement
|
30 Aug 2024 5:42PM |
$26.020 |
$26.050 |
risen by
0.12%
|
|
| Amani Gold Limited (ANL) ORDINARY FULLY PAID |
Materials |
- |
Equal Access Buy Back - Offer Booklet
|
30 Aug 2024 5:41PM |
$0.001 |
$0.001 |
fallen by
0%
|
|
| Atomos Limited (AMS) ORDINARY FULLY PAID |
Consumer Discretionary |
$6 |
FY2024 Results - Reset and relaunch
|
30 Aug 2024 5:41PM |
$0.043 |
$0.005 |
fallen by
88.37%
|
|
AMS - Price-sensitive ASX Announcement
Full Release
Key Points
- FY24 revenue was $35.7m, down 16% on FY23
- Substantial improvement in gross profit margin from 11% in FY23 to 31% in FY24
- Developed and announced two new products: Ninja Phone and SunDragon
- Completed $16.2m capital raise and resumed ASX trading on 21 May 2024
- Cost restructuring reduced staff from 90 to 70 by 30 June 2024
- Cash balance of $2.9m as of 30 June 2024 with no debt
- New management led by returning founder Jeromy Young
- Targeting EBITDA breakeven at around $45m of sales in FY25
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Algorae Pharmaceuticals Limited (1AI) ORDINARY FULLY PAID |
Health Care |
$10 |
Annual Report and Appendix 4E
|
30 Aug 2024 5:40PM |
$0.008 |
$0.006 |
fallen by
25%
|
|
1AI - Price-sensitive ASX Announcement
Full Release
Key Points
- Development of AlgoraeOS AI platform with UNSW
- Algorae retains 100% ownership of project intellectual property
- Algorae becomes a participant in CSIRO Next Generation AI Graduate Program
- Financial results for the year ended 30 June 2024
- Positive pre-clinical results for AI-116 drug candidate for dementia
- Research agreement with Monash University for AI-168 drug candidate
- Engagement with HL Pharma to warehouse cannabinoid compounds
- Termination of agreement with NZeno Limited
- Financial position and net asset decrease
- Business strategy and prospects for future years
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| First Graphene Limited (FGR) ORDINARY FULLY PAID |
Materials |
$29 |
Cleansing Statement SMI
|
30 Aug 2024 5:39PM |
$0.049 |
$0.039 |
fallen by
20.41%
|
|
| BetaShares Western Asset Australian Bond Fund (Managed Fund) (BNDS) |
Financials |
$822 |
Final Distribution Announcement
|
30 Aug 2024 5:38PM |
$23.870 |
$23.680 |
fallen by
0.80%
|
|
| Atomos Limited (AMS) ORDINARY FULLY PAID |
Consumer Discretionary |
$6 |
Preliminary Final Report
|
30 Aug 2024 5:38PM |
$0.043 |
$0.005 |
fallen by
88.37%
|
|
AMS - Price-sensitive ASX Announcement
Full Release
Key Points
- Atomos Ltd's revenue declined by $7.0 million in FY24, a 16% decrease compared to the previous corresponding period.
- The company's gross profit for FY24 was $11.2 million, which is $6.5 million higher than the previous year, with a gross profit margin of 31% compared to 11% in the previous year.
- No dividends were paid during the period, and no dividends are proposed to be paid.
- Reported EBITDA loss for FY24 was $17.3 million, an improvement from a $25.5 million loss in the previous year.
- Atomos Ltd issued new shares and raised $16.2 million to bolster its financial position.
- Management is focused on delivering new products to market and educating customers on their benefits.
- Revenue in the second half of FY24 increased by 5.1% compared to the first half of the year.
- The company reduced staff from 90 to under 70 permanent staff as part of a cost restructure.
- Net tangible assets per security decreased to 0.3 cents in FY24 from 2.7 cents in FY23.
- The annual general meeting of Atomos Ltd is scheduled for 28 November 2024.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Hydrix Limited (HYD) ORDINARY FULLY PAID |
Information Technology |
$4 |
Preliminary Final Report and Market Update
|
30 Aug 2024 5:38PM |
$0.011 |
$0.015 |
risen by
36.36%
|
|
HYD - Price-sensitive ASX Announcement
Full Release
Key Points
- Hydrix Limited released its Appendix 4E and Preliminary Final Report for the year ending 30 June 2024.
- The company reported revenues of $10.6 million, a 19% decrease from the previous year.
- 73% of revenues came from Europe and the USA, marking significant international sales progress.
- Five-unit sales of the proprietary LUDO mechanical heart controllers were made.
- The company has a future revenue potential of approximately $40 million from 15 clients.
- Hydrix Medical's sales opportunity pipeline could generate more than $2.5 million in annual recurring revenues from remote cardiac patient monitoring software.
- As of 30 June 2024, the company had $0.9 million cash on hand and recorded a customer receipt of $12.3 million for the year.
- The group saw a 31% improvement in net cash used in operating activities, down to $1.9 million.
- The group recorded a loss from ordinary activities after tax of $9.6 million.
- Hydrix Ventures ended the year with a $3.35 million asset book value.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Mayfield Childcare Limited (MFD) ORDINARY FULLY PAID |
Consumer Discretionary |
$34 |
Dividend/Distribution - MFD
|
30 Aug 2024 5:36PM |
$0.655 |
$0.450 |
fallen by
31.30%
|
|
| First Graphene Limited (FGR) ORDINARY FULLY PAID |
Materials |
$29 |
Application for quotation of securities - FGR
|
30 Aug 2024 5:36PM |
$0.049 |
$0.039 |
fallen by
20.41%
|
|
| Anagenics Limited (AN1) ORDINARY FULLY PAID |
Consumer Staple |
$3 |
FY24 4E Presentation
|
30 Aug 2024 5:35PM |
$0.008 |
$0.006 |
fallen by
25%
|
|
AN1 - Price-sensitive ASX Announcement
Full Release
Key Points
- $10.9m revenue, a 10.6% increase from FY23
- Underlying EBITDA loss of $2.9M
- Impairments and abnormal write-offs totaling $4.2M
- Business restructuring and cost reduction efforts
- Completion of share placement and new investor introductions
- Cash position of $1.6M as of June 2024
- Streamlining portfolio focusing on exclusive ANZ wholesale distribution and strategic brand development
- Long-term licensing agreement with YSB and royalty income from Roquefort Therapeutics
- FY24 revenue of $10.8M and gross profit margin of 40%
- EBITDA operating loss of $7.3M and EBIT loss of $7.7M
- Significant impairments of intangible assets
- FY24 focused on strategic review and execution of new royalty agreements
- FY25 plans to focus on simplified and sustainable business model
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Orbital Corporation Limited (OEC) ORDINARY FULLY PAID |
Industrials |
$15 |
Appendix 4G & Corporate Governance Statement
|
30 Aug 2024 5:34PM |
$0.085 |
$0.089 |
risen by
4.71%
|
|
| Orbital Corporation Limited (OEC) ORDINARY FULLY PAID |
Industrials |
$15 |
FY24 Annual Report & Appendix 4E
|
30 Aug 2024 5:34PM |
$0.085 |
$0.089 |
risen by
4.71%
|
|
OEC - Price-sensitive ASX Announcement
Full Release
Key Points
- Delivery of $15.7M revenue and other income
- Net profit after tax of $0.1M
- Successful Equity raise of $4M with new cornerstone shareholders
- Achievement of milestones for WA government loan valuing $1.5M
- Improved Net Asset position from $6.9M to $10.8M
- Closing cash and equivalents position of $4.8M
- Operational revenue of $12.6M primarily from the export of heavy fuel engine models
- Equity offer in September 2023 raised $4M
- Net cash outflow from operating activities was $0.03M
- Net cash inflow from financing activities was $3.3M
- Total Debt position decreased to $2.4M
- No proposal to pay dividends for the year ended 30 June 2024
- Material uncertainty exists regarding the Group’s ability to continue as a going concern
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| TMK Energy Limited (TMK) ORDINARY FULLY PAID |
Energy |
$31 |
Notification of cessation of securities - TMK
|
30 Aug 2024 5:33PM |
$0.004 |
$0.003 |
fallen by
25%
|
|
| Anagenics Limited (AN1) ORDINARY FULLY PAID |
Consumer Staple |
$3 |
Appendix 4E and Preliminary Final Report
|
30 Aug 2024 5:33PM |
$0.008 |
$0.006 |
fallen by
25%
|
|
AN1 - Price-sensitive ASX Announcement
Full Release
Key Points
- Operating results for Anagenics Limited for the year ended 30 June 2024.
- Meaningful sales growth achieved both organically and through acquisition.
- Reduction of inventory levels and normalization of liabilities.
- Restructuring challenges with FMG integration affecting gross margins.
- Significant restructuring and impairments leading to an operating loss after tax of $7,744,206.
- Underlying EBITDA loss normalized for restructuring costs totaled $2,865,285.
- Net cash used in operating activities was $1,738,321.
- Closing cash and cash equivalents at hand were $1,653,925.
- Loss of control over entity Advangen Incorporated (Japan) on 31 July 2022.
- No dividends paid, recommended, or declared during the financial period.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| IRIS Metals Limited (IR1) ORDINARY FULLY PAID |
Materials |
$24 |
Clarification Announcement - Updated Investor Presentation
|
30 Aug 2024 5:32PM |
$0.180 |
$0.140 |
fallen by
22.22%
|
|
IR1 - Price-sensitive ASX Announcement
Full Release
Key Points
- IRIS Metals Limited (ASX: IR1) retracts AGM Investor Presentation released on 30 August 2024 following consultation with ASX.
- New Investor Presentation includes a Competent Person's Statement and references to prior exploration results.
- The Beecher Project completed 50 RC drill holes and 59 diamond core holes totaling nearly 9,000m.
- Best drill hole at Beecher: 75.1m at 1.41% Li2O from 25.1m.
- Tin Mountain Project secured in January 2024, drill permit received in August 2024, 26 hole, 1,560m drill program planned.
- Maiden mineral resource estimate for both Beecher and Tin Mountain Projects expected in Q1 2025.
- IRIS advancing mineral processing studies and early-stage development work for lithium carbonate and/or lithium hydroxide production.
- IRIS controls significant land holdings in Black Hills, South Dakota, with potential for substantial growth.
- Company's South Dakota project positioned to benefit from US government incentives for locally sourced critical minerals.
- IRIS Metals' Board of Directors includes experienced professionals in corporate advisory, mining operations, and strategic mineral projects.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| RocketBoots Limited (ROC) ORDINARY FULLY PAID |
Information Technology |
$11 |
Notification regarding unquoted securities - ROC
|
30 Aug 2024 5:31PM |
$0.100 |
$0.078 |
fallen by
22%
|
|
| Bougainville Copper Limited (BOC) 1 KINA ORDINARY FULLY PAID |
Materials |
$128 |
Half Yearly Report and Accounts
|
30 Aug 2024 5:31PM |
$0.455 |
$0.320 |
fallen by
29.67%
|
|
BOC - Price-sensitive ASX Announcement
Full Release
Key Points
- Bougainville Copper Limited (BOC) reported a net operating loss of K6.3 million (AUD$2.5m) for the six months ended 30 June 2024.
- The loss increased from K4.2 million (AUD$1.7m) in the same period in 2023.
- Income from dividends and interest was K1.58 million, down from K1.65 million in 2023.
- General and administration expenses increased to K7.65 million from K5.52 million in 2023.
- The company's exploration licence for the Panguna project area was extended for five years on 31 January 2024.
- Bougainville Copper is involved in a class action lawsuit in PNG’s National Court related to environmental and social harm from the Panguna mine.
- The company has no outstanding borrowings as of 30 June 2024.
- Bougainville Copper Foundation has resumed awarding scholarships, with 23 scholarships granted in 2024.
- Community engagement and support activities include sponsoring local festivals and supporting educational programs.
- No dividend was declared for the six months ended 30 June 2024.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Sportshero Limited (SHO) ORDINARY FULLY PAID |
Communication Services |
$21 |
Preliminary Final Report
|
30 Aug 2024 5:31PM |
$0.006 |
$0.029 |
risen by
383.33%
|
|
SHO - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue increase to $399,797
- Loss after tax from continuing operations reduced to $623,572
- No dividends declared or paid
- Three-year revenue share agreement with the Football Association of Indonesia
- Partnership with IGVault HK Limited
- Securities issued to Mr. Stratos Karousos and other shares raising $551,992
- Research and Development reimbursement received from the Australian Tax Office
- Changes in company officers announced
- Advertising revenues generated through KitaGaruda app managed by Whisper Media
- Confirmed advertising contracts and sponsorship renewals with major brands
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Hydrix Limited (HYD) ORDINARY FULLY PAID |
Information Technology |
$4 |
Appendix 4E
|
30 Aug 2024 5:29PM |
$0.011 |
$0.015 |
risen by
36.36%
|
|
HYD - Price-sensitive ASX Announcement
Full Release
Key Points
- Hydrix Limited reported financial results for the year ended 30 June 2024.
- Revenue decreased by 19.5% to $10.7 million.
- The company incurred a net loss before tax of $9.56 million.
- Hydrix Services had a strong sales pipeline despite a revenue drop.
- Hydrix Medical focused on market awareness and sales pipeline for Implicity remote cardiac monitoring.
- Hydrix Ventures made no new investments and focused on existing portfolio companies.
- International revenues increased significantly, making up 73% of total revenues.
- Total operating costs decreased by $1.04 million to $16.2 million.
- Significant non-cash impairments and fair value adjustments impacted financial results.
- The company had a cash balance of $914,274 at the end of the fiscal year.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Unith Ltd (UNT) ORDINARY FULLY PAID |
Communication Services |
$15 |
Appendix 4E & Annual Report to shareholders
|
30 Aug 2024 5:29PM |
$0.020 |
$0.012 |
fallen by
40%
|
|
UNT - Price-sensitive ASX Announcement
Full Release
Key Points
- Corporate Governance Statement and policies are available on the company's website
- UNITH's Digital Human platform saw significant user testing and feedback in H2 FY24
- B2C Subscription division generated $4.2 million revenue in FY24
- UNITH’s EBITDA was ($0.58 million) due to investment in the Digital Human platform
- UNITH raised $4.57 million for launching interFace and marketing
- Net asset position of $11.9 million, including a $1.9 million fair value gain from AudioStack investment
- Directors’ report includes details on revenue growth and segment performance
- No dividends were declared or paid in FY24
- Net tangible assets per ordinary security decreased from 0.86 cents to 0.82 cents
- Loss after income tax amounted to $1,888,963
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Green Critical Minerals Limited (GCM) ORDINARY FULLY PAID |
Materials |
$27 |
Appendix 4G and Corporate Governance Statement
|
30 Aug 2024 5:28PM |
$0.003 |
$0.014 |
risen by
460%
|
|
| BCAL Diagnostics Limited (BDX) ORDINARY FULLY PAID |
Health Care |
$30 |
Appendix 4E and Annual Report to Shareholders
|
30 Aug 2024 5:27PM |
$0.125 |
$0.082 |
fallen by
34.40%
|
|
BDX - Price-sensitive ASX Announcement
Full Release
Key Points
- BCAL Diagnostics Limited is transitioning from research and development to becoming a commercial healthcare service provider.
- The company is preparing for the commercial launch of their breast cancer diagnostic blood test, BREASTEST®, in Australia by late 2024.
- BCAL raised $13.5 million in capital during the financial year to support clinical studies, laboratory development, and general working capital.
- The company is also expanding into the US market with laboratory facilities in North Carolina, set to open in September 2024.
- BCAL has formed a National Key Opinion Leader network and established multiple clinical partnerships to support their product development and market entry.
- Significant investment has been made in technology and sample collection, with over 5,000 samples collected to date from various regions.
- BCAL has secured several patents and trademarks to protect its intellectual property, including the BREASTEST® name and associated technologies.
- The company has appointed new key personnel, including a Chief Executive Officer and a Director of US Research and Product Development, to lead the commercialization efforts.
- BCAL is on track to receive NATA accreditation for their clinical laboratory in Sydney, which is crucial for the development and performance of in-house diagnostics.
- The financial performance for the year ended 30 June 2024 showed a net loss after tax of $6.4 million, with shareholder equity increasing to $8.59 million.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Chimeric Therapeutics Limited (CHM) ORDINARY FULLY PAID |
Health Care |
$15 |
Notice under section 708A
|
30 Aug 2024 5:27PM |
$0.017 |
$0.008 |
fallen by
52.94%
|
|
| Freedom Care Group Holdings Limited (FCG) ORDINARY FULLY PAID |
Health Care |
$1 |
Preliminary Final Report
|
30 Aug 2024 5:26PM |
$0.140 |
$0.037 |
fallen by
73.57%
|
|
FCG - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenues from ordinary activities increased by 39.0% to $32,835,000
- Profit for the year attributable to owners decreased by 56.3% to $1,161,000
- No dividends were paid, recommended, or declared during the financial period
- Net tangible assets per ordinary security decreased to 4.70 cents
- Total comprehensive income for the year was $1,226,000
- Cash and cash equivalents at the end of the year were $4,142,000
- Total assets increased to $9,098,000
- Total liabilities increased to $3,664,000
- Issued capital increased to $4,334,000
- Earnings per share decreased to 1.07 cents
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
Goals & planningInvesting goal hubsSaving to build wealth
Saving for happy retirement 
Call 1300 880 160
Start a chat
Schedule a call
